Objective: To determine the efficacy of topical Nepafenac 0.1% eye drops in terms of mean change in central macular thickness (CMT) in patients of diabetic macular edema (DME).
Study Design: Quasi Experimental Study.
Place and Duration of Study: Armed Forces Institute of Ophthalmology (AFIO) Rawalpindi from 1st Dec 2011 to 31st July 2012.
Patients and Methods: One hundred and fifty eyes of 150 patients that fulfilled the laid down criteria were enrolled. Baseline central macular thickness (CMT) recording of diabetic macular edema (DME) patients was carried out with the help of Optical Coherence Tomography (OCT). Topical Nepafenac 0.1% eye drops were started as a single drop 8 hourly for 4 weeks. CMT was recorded at two and four weeks after initiation of treatment. Efficacy of the drug will be considered if decrease in CMT is 15 microns or more after 4 weeks of treatment, as measured by OCT. Paired sample t-test was used to compare pre- and post-treatment CMT from baseline to 2 weeks and 4 weeks.
Results: All patients completed the follow up. At 2 weeks, mean CMT reduction was 1.48 microns (SD=15.94 microns) and at the end of week 4 CMT was reduced by 2.76 microns (SD=18.66 microns).The p value at week 2 (0.257) and week 4 (0.072) was statistically insignificant.
Conclusion: Efficacy of topical Nepafenac 0.1% eye drops was seen in 34.67% of cases however it does not confers statistically significant benefit in terms of mean change in CMT after 4 weeks of treatment
Bevacizumab, Diabetic macular edema, Nepafenac.